版本:
中国

BRIEF-Intra-Cellular Therapies provides corporate update on schizophrenia program

May 1 Intra-cellular Therapies Inc:

* Intra-Cellular Therapies provides corporate update on schizophrenia program

* Intra-Cellular Therapies - FDA confirmed results of study iti-007-302 do not preclude co from submitting NDA based on efficacy studies conducted to date

* Intra-Cellular Therapies - FDA requested information to confirm nonclinical findings are not indicative of safety risk related to long term exposure in humans

* FDA has not raised any safety concerns regarding study of lumateperone in short term treatment trials in humans

* Intra-Cellular Therapies - if FDA deems responses for nonclinical findings sufficient, to submit NDA for lumateperone for treating schizophrenia by mid-year 2018 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐